James P. Allison, Ph.D., Professor of Immunology, University of California at Berkeley
Mark M. Davis, Ph.D., Professor of Microbiology and Immunology, Stanford University Medical Center
Philip D. Greenberg, M.D., Professor of Medicine (Oncology), Fred Hutchinson Cancer Research Center
Leroy Hood, M.D., Ph.D., President, Institute for Systems Biology
Stanley R. Riddell, M.D., Associate Professor, University of Washington School of Medicine
Irving L. Weissman, M.D. (Chair), Professor of Cancer Biology, Pathology and Developmental Biology, Stanford University
James P. Allison, Ph.D., has a longstanding interest in mechanisms of T-cell development and activation, and the development of novel strategies for tumor immunotherapy. He was the first person to isolate the T-cell antigen receptor protein, a feat which has been called one of the three most important findings in immunology in the last 20 years. He has made many contributions to our understanding of the regulation of the early events in T-cell activation. His work over the last several years has demonstrated that this process is considerably more complex than originally thought and involves integration of the at least three signals. Dr. Allison was the first to show that one of the reasons that tumor cells are able to avoid immune responses is that they lack the molecules that provide the CD28 mediated co-stimulatory signals. More recently, he has shown that blockade of the inhibitory signals of CTLA-4 can greatly enhance immune responses, including those directed against tumors. He is a member of the National Academy of Science, a Fellow of the American Academy of Microbiology and has received numerous awards, including the 2001 Centeon Award for Innovative Breakthroughs in Immunology. From 2001–2002, he served as President of the American Association of Immunologists.
Mark M. Davis, Ph.D., has a Ph.D. in Molecular Biology from the California Institute of Technology. He is currently a Professor of Microbiology and Immunology at Stanford University and an Investigator with the Howard Hughes Medical Institute. One of the world’s leading authorities on T-cell recognition, both basic and applied, Dr. Davis and his colleagues recently developed the widely used “tetramer” reagents as tools with which to directly visualize and analyze T-cells which are responding to specific pathogens or markers on cancerous cells. He is the recipient of numerous honors and awards, including membership in the National Academy of Science and the Alfred D. Sloane Prize of the General Motors Cancer Research Foundation. He is also Chairman of the Microbiology & Immunology Department at Stanford Medical School.
Philip D. Greenberg, M.D., is Professor of Medicine (Oncology) and Immunology at the University of Washington and Member of the Fred Hutchinson Cancer Research Center (FHCRC). Dr. Greenberg graduated from Washington University with a degree in biology. He received his M.D. summa cum laude from the State University of New York, Downstate Medical Center, in 1971. After completing postdoctoral training at the University of California at San Diego, he joined the FHCRC and the Division of Oncology at the University of Washington in 1976. Since 1988 he has also served as the Director of the Immunology Program at the FHCRC and Co-Director of the Immunology Program for UW Center for AIDS Research.
Leroy Hood, M.D., Ph.D., is President of the Institute for Systems Biology in Seattle, Washington. Dr. Hood’s research has focused on the study of molecular immunology, biotechnology, and genomics. His professional career began at Caltech where he and his colleagues pioneered four instruments—the DNA gene sequencer and synthesizer, and the protein synthesizer and sequencer—which comprise the technological foundation for contemporary molecular biology. In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s. In 1992, Dr. Hood moved to the University of Washington as founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology. In 2000, he co-founded the Institute for Systems Biology in Seattle, Washington to pioneer systems approaches to biology and medicine. Most recently, Dr. Hood's lifelong contributions to biotechnology have earned him the prestigious 2003 Lemelson–MIT Prize for Innovation and Invention. He was also awarded the 2002 Kyoto Prize in Advanced Technology and the 1987 Lasker Prize for his studies on the mechanism of immune diversity. He has published more than 500 peer-reviewed papers, received 12 patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics, and is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, and the Institute of Medicine. Dr. Hood has also played a role in founding numerous biotechnology companies, including Amgen, Applied Biosystems, SyStemix, Darwin and Rosetta.
Stanley R. Riddell, M.D., is a member of the faculty at the Fred Hutchinson Cancer Research Center (FHCRC) and Professor at the University of Washington School of Medicine, a position to which he was appointed in 2000. He is the recipient of the ASCO Young Investigator Award and the Cancer Research Institute Partridge Foundation Investigator Award. He is a member of the American Association for the Advancement of Science, the American Society of Gene Therapy, and the American Society of Hematology. Dr. Riddell earned his M.D. at the University of Manitoba and is a Board Certified Medical Oncologist.
Irving L. Weissman, M.D., (Chair of the Scientific Advisory Board) is the Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research at Stanford University. He is also the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. His research encompasses the developmental biology, self-renewal, homing, and functions of the cells that make up the blood-forming and immune systems. His main focus for the last several years has been the isolation, biology, transplantation, and evolution of stem cells. His Stanford lab was the first to isolate any stem cell from any tissue in any species. The isolation of mouse HSCs was followed by the isolation of human HSC by Dr. Weissman and his colleagues at SyStemix where he was a co-founder and director. He has also served on the founding scientific advisory boards of Amgen Inc., DNAX, Inc., and T-Cells Sciences, Inc. (now Avant, Inc.). He was a co-founder and is currently a member of the board of directors of StemCells, Inc., where he is co-inventor of the human brain stem cell composition. Dr. Weissman has been elected to the National Academy of Sciences, the Institute of Medicine of the National Academies, and to the American Association for the Arts and Sciences. He has received the Kaiser Award for Excellence in Preclinical Teaching, the Pasarow Award for cancer research, the Outstanding Investigator Award from the National Institutes of Health, the E. Donnall Thomas Award for Outstanding Achievement in Hematology, the deVilliers Award for Outstanding Achievements in Leukemia Research, the J. Allyn Taylor International Prize in Medicine, the American Diabetes Association Elliott Proctor Joslin Medal, and the Society of Neurological Surgeons Bass Award. In 2002 he was awarded the California Scientist of the Year, covering all fields, and in 2004 was awarded the Rabbi Shai Shacknai Memorial Prize in Immunology and Cancer Research from the Lautenberg Center for General and Tumor Immunology, and the Jessie Stevenson Kovalenko Medal from the National Academy of Sciences Council. He is also the 2004 Alan Cranston Awardee from the Alliance for Aging Research, and the 2005 recipient of the Linus Pauling Medal for Outstanding Contributions to Science from Stanford University.